Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 3:41 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: haloperidol decanoate Clear all
Completed Not applicable Interventional Accepts healthy volunteers

Pre-hospital Agitation and Sedation Trial: A Randomized Controlled Trial of Haloperidol Versus Midazolam for the Sedation of the Agitated Patient

NCT01501123
View directory record Official record
Conditions
Agitation
Interventions
Haloperidol, Midazolam
Drug
Lead sponsor
Catholic Health East
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2015
U.S. locations
1
States / cities
Darby, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 23, 2019 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

Inhaled Loxapine vs Intramuscular (IM) Haloperidol + Lorazepam for Agitation

NCT03110900
View directory record Official record
Conditions
Agitation,Psychomotor, Haloperidol Causing Adverse Effects in Therapeutic Use, Lorazepam Causing Adverse Effects in Therapeutic Use, Loxapine Causing Adverse Effects in Therapeutic Use
Interventions
Haloperidol + lorazepam, Loxapine
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 65 Years
Enrollment
2 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated Jun 10, 2018 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated Phase 4 Interventional Results available

Efficacy of Haloperidol vs. Metoclopramide for Treatment of Acute Headaches and Migraines in the Emergency Department

NCT02972502
View directory record Official record
Conditions
Headache, Migraine
Interventions
Metoclopramide, Haloperidol, Normal Saline, Diphenhydramine
Drug · Other
Lead sponsor
OhioHealth
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 22, 2018 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated Phase 4 Interventional

Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia

NCT00169091
View directory record Official record
Conditions
Schizophrenia
Interventions
Clozapine, Haloperidol
Drug
Lead sponsor
Harvard Medical School (HMS and HSDM)
Other
Eligibility
18 Years to 45 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Jamaica Plain, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 3 Interventional Results available

The Modifying the Impact of ICU-Associated Neurological Dysfunction-USA (MIND-USA) Study

NCT01211522
View directory record Official record
Conditions
Delirium, Impaired Cognition, Long Term Psychologic Disorders
Interventions
Haloperidol, Ziprasidone, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years and older
Enrollment
566 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2019 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Not applicable Interventional Results available

A Concierge Model of CAE Plus LAI in Individuals With Schizophrenia at Risk for Treatment Non-adherence and Homelessness

NCT02085447
View directory record Official record
Conditions
Psychotic Disorders, Schizophrenia, Schizoaffective Disorder, Medication Adherence, Medication Non-Adherence
Interventions
CAE-L
Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 8, 2019 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated Phase 4 Interventional Results available

Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

NCT02343575
View directory record Official record
Conditions
Hyperactive Delirium, Mixed Delirium
Interventions
Valproic Acid, Placebo, Haloperidol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Not applicable Interventional Results available

Randomized Trial of the Effectiveness of Topical "ABH Gel" vs. Placebo in Cancer Patients With Nausea

NCT01556932
View directory record Official record
Conditions
Nausea, Vomiting
Interventions
ABH gel, placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2015 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated No phase listed Observational

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

NCT02893371
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium Carbonate, Lamotrigine, Valproic Acid, Oxcarbazepine, Carbamazepine, Ziprasidone, Risperidone, Quetiapine, Olanzapine, Aripiprazole, Fluoxetine / Olanzapine, Haloperidol, Perphenazine, Clozapine, Asenapine, Lurasidone, Paliperidone, Mirtazapine, Bupropion, Desvenlafaxine, Duloxetine, Venlafaxine, Citalopram, Escitalopram, Fluoxetine, Fluvoxamine, Paroxetine, Sertraline, Vilazodone, Doxepin
Drug
Lead sponsor
University of New Mexico
Other
Eligibility
Not listed
Enrollment
1,037,352 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 11, 2024 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 4 Interventional

To Determine if Olanzapine is More Cost Effective Than Haloperidol for the Treatment of Schizophrenia

NCT00007774
View directory record Official record
Conditions
Schizoaffective Disorder, Schizophrenia
Interventions
Haloperidol, Olanzapine
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
Not listed
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
18
States / cities
Tuscaloosa, Alabama • Palo Alto, California • West Haven, Connecticut + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2009 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated Phase 3 Interventional

Treatment of Major Depressive Disorder With Psychotic Features.

NCT00174590
View directory record Official record
Conditions
Major Depression With Psychotic Features
Interventions
risperidone
Drug
Lead sponsor
Rush University Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2007
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 9, 2008 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Effect of Opioid Free Anesthetic on Post-Operative Opioid Consumption After Laparoscopic Bariatric Surgery

NCT04081545
View directory record Official record
Conditions
Opioid Use, Unspecified, Bariatric Surgery Candidate, Anesthesia
Interventions
Opioid Anesthetics, Non Opioid Analgesics
Drug
Lead sponsor
Christine Oryhan
Other
Eligibility
18 Years and older
Enrollment
181 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 26, 2026, 3:41 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Haloperidol and Lorazepam for Delirium in Patients With Advanced Cancer

NCT01949662
View directory record Official record
Conditions
Advanced Cancers
Interventions
Lorazepam, Placebo, Haloperidol decanoate, Questionnaires
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
93 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Ziprasidone vs. Sertraline/Haloperidol in Psychotic Depression

NCT00340379
View directory record Official record
Conditions
Affective Disorders
Interventions
Ziprasidone, Sertraline, Haloperidol
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years to 75 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2005
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 18, 2014 · Synced Sep 26, 2026, 3:41 PM EDT
Terminated Phase 2 Interventional Results available

Meth-OD: A Study of IXT-m200 in Patients With Toxicity From Methamphetamine Overdose

NCT04715230
View directory record Official record
Conditions
Methamphetamine Intoxication (Disorder)
Interventions
IXT-m200, Lorazepam, Haloperidol
Biological · Drug
Lead sponsor
InterveXion Therapeutics, LLC
Industry
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
4
States / cities
Little Rock, Arkansas • Albuquerque, New Mexico • Everett, Washington + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Not applicable Interventional Results available

Customized Adherence Enhancement Plus Long-acting Injectable Antipsychotic

NCT01152697
View directory record Official record
Conditions
Patient Noncompliance
Interventions
haloperidol decanoate, haloperidol, Customized Adherence Enhancement
Drug · Behavioral
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Dec 29, 2014 · Synced Sep 26, 2026, 3:41 PM EDT
Recruiting Phase 3 Interventional

Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department

NCT07246187
View directory record Official record
Conditions
Cannabinoid Hyperemesis Syndrome
Interventions
Olanzapine 10 milligram, Haloperidol
Drug
Lead sponsor
Mercy Bon Secours Saint Vincent Medical Center
Other
Eligibility
18 Years to 100 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Toledo, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 23, 2025 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 2 Interventional Results available

A Comparison of Study Drug With Placebo and Haloperidol in Patients With Schizophrenia

NCT00044044
View directory record Official record
Conditions
Schizophrenia
Interventions
Lurasidone 20 mg, Lurasidone 40mg, Lurasidone 80 mg, Haloperidol 10mg, Placebo
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
356 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
34
States / cities
Birmingham, Alabama • Cerritos, California • Garden Grove, California + 26 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2014 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 4 Interventional

Treatment of Obsessive-Compulsive Disorder

NCT00000373
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
olanzapine + fluoxetine, placebo + fluoxetine
Drug
Lead sponsor
University of Florida
Other
Eligibility
14 Years to 70 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 2003
U.S. locations
2
States / cities
Gainesville, Florida • Jacksonville, Florida
Source: ClinicalTrials.gov public record
Updated Nov 26, 2013 · Synced Sep 26, 2026, 3:41 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Haloperidol and Lorazepam in Controlling Symptoms of Persistent Agitated Delirium in Patients With Advanced Cancer Undergoing Palliative Care

NCT03743649
View directory record Official record
Conditions
Delirium, Locally Advanced Malignant Neoplasm, Metastatic Malignant Neoplasm, Recurrent Malignant Neoplasm
Interventions
Haloperidol, Lorazepam, Placebo, Quality-of-Life Assessment, Questionnaire Administration
Drug · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
2
States / cities
Houston, Texas • Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2026 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Lorazepam, Diphenhydramine Hydrochloride, and Haloperidol Gel in Healthy Volunteers

NCT01204255
View directory record Official record
Conditions
Healthy
Interventions
lorazepam, diphenhydramine hydrochloride, haloperidol, questionnaire administration, laboratory biomarker analysis
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Sep 26, 2026, 3:41 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Bone Mineral Content and Bone Metabolism in Adolescents on Antipsychotic Therapy

NCT00399776
View directory record Official record
Conditions
Adolescent Depression
Interventions
Bone Density Test
Radiation
Lead sponsor
Creighton University
Other
Eligibility
10 Years to 17 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2009
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Aug 3, 2011 · Synced Sep 26, 2026, 3:41 PM EDT
Completed No phase listed Observational

A Study to Assess Stroke Risk Among Users of Typical Versus Atypical Antipsychotics Stratified by Broad Age Group

NCT04002700
View directory record Official record
Conditions
Stroke
Interventions
Haloperidol, Typical Antipsychotics, Atypical Antipsychotics
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,234,412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 24, 2025 · Synced Sep 26, 2026, 3:41 PM EDT
Completed Phase 4 Interventional Results available

A Comparison Study of the Efficacy of Quetiapine and Haloperidol in Agitated Adults in Emergency Room

NCT00457366
View directory record Official record
Conditions
Agitation
Interventions
Quetiapine, Haloperidol, Lorazepam, Cogentin
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Jul 25, 2019 · Synced Sep 26, 2026, 3:41 PM EDT